Endoglin: Beyond the Endothelium, PMID: 32059544
Endoglin Targeting: Lessons Learned and Questions That Remain, PMID: 33375670
Endoglin-targeted cancer therapy, PMID: 21034418
An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial), PMID: 30357394
Antibodies to watch in 2018, PMID: 29300693
Endoglin for targeted cancer treatment, PMID: 24445497
Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR), PMID: 33829609
Anti-angiogenesis in prostate cancer: knocked down but not out, PMID: 24759579
The Role of Endoglin in Hepatocellular Carcinoma, PMID: 33809908
Antagonizing CD105 enhances radiation sensitivity in prostate cancer, PMID: 29717261
Targeting angiogenesis for radioimmunotherapy with a 177 Lu-labeled antibody, PMID: 28821931
86/90 Y-Based Theranostics Targeting Angiogenesis in a Murine Breast Cancer Model, PMID: 29787283
Novel Preparation Methods of (52)Mn for ImmunoPET Imaging, PMID: 26317429
Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler-Weber-Rendu Syndrome, PMID: 30139834
Red fluorescent zinc oxide nanoparticle: a novel platform for cancer targeting, PMID: 25607242
Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells, PMID: 31068371
Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer, PMID: 28832978
In vivo tumor vasculature targeted PET/NIRF imaging with TRC105(Fab)-conjugated, dual-labeled mesoporous silica nanoparticles, PMID: 24937108
Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer, PMID: 26804178
Effects of the combination of TRC105 and bevacizumab on endothelial cell biology, PMID: 24994097
Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105, PMID: 29997150
Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models, PMID: 28351936
PET Imaging of Abdominal Aortic Aneurysm with 64Cu-Labeled Anti-CD105 Antibody Fab Fragment, PMID: 25883125
Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy, PMID: 24875656
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma, PMID: 28465443
A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer, PMID: 25407442
A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma, PMID: 27328856
Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer, PMID: 24574330
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer, PMID: 22767667
Positron emission tomography imaging of angiogenesis in a murine hindlimb ischemia model with 64Cu-labeled TRC105, PMID: 23738915
An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer, PMID: 25261556
Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescence, PMID: 23471463
Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling, PMID: 24077288
Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute, PMID: 29217138
High Yield Production and Radiochemical Isolation of Isotopically Pure Arsenic-72 and Novel Radioarsenic Labeling Strategies for the Development of Theranostic Radiopharmaceuticals, PMID: 26646989
CD105 blockade restores osimertinib sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer., PMID:40090182
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial., PMID:37684373
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer., PMID:36735117
Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells., PMID:36160139
Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit., PMID:36045587
High-precision tumor resection down to few-cell level guided by NIR-IIb molecular fluorescence imaging., PMID:35380898
Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial., PMID:35357396
Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study., PMID:34935908
Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)., PMID:33829609
The Role of Endoglin in Hepatocellular Carcinoma., PMID:33809908
Endoglin Targeting: Lessons Learned and Questions That Remain., PMID:33375670
Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy., PMID:32332012
Endoglin: Beyond the Endothelium., PMID:32059544
Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells., PMID:31068371
An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial)., PMID:30357394
Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler-Weber-Rendu Syndrome., PMID:30139834
Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105., PMID:29997150
86/90Y-Based Theranostics Targeting Angiogenesis in a Murine Breast Cancer Model., PMID:29787283
Antagonizing CD105 enhances radiation sensitivity in prostate cancer., PMID:29717261
Antibodies to watch in 2018., PMID:29300693
Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute., PMID:29217138
Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer., PMID:28832978
Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody., PMID:28821931
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma., PMID:28465443
Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models., PMID:28351936
A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma., PMID:27328856
Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer., PMID:26804178
High Yield Production and Radiochemical Isolation of Isotopically Pure Arsenic-72 and Novel Radioarsenic Labeling Strategies for the Development of Theranostic Radiopharmaceuticals., PMID:26646989
Novel Preparation Methods of (52)Mn for ImmunoPET Imaging., PMID:26317429
PET Imaging of Abdominal Aortic Aneurysm with 64Cu-Labeled Anti-CD105 Antibody Fab Fragment., PMID:25883125
Red fluorescent zinc oxide nanoparticle: a novel platform for cancer targeting., PMID:25607242
A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer., PMID:25407442
An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer., PMID:25261556
Effects of the combination of TRC105 and bevacizumab on endothelial cell biology., PMID:24994097
In vivo tumor vasculature targeted PET/NIRF imaging with TRC105(Fab)-conjugated, dual-labeled mesoporous silica nanoparticles., PMID:24937108
Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy., PMID:24875656
Anti-angiogenesis in prostate cancer: knocked down but not out., PMID:24759579
Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer., PMID:24574330
Endoglin for targeted cancer treatment., PMID:24445497
Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling., PMID:24077288
Positron emission tomography imaging of angiogenesis in a murine hindlimb ischemia model with 64Cu-labeled TRC105., PMID:23738915
Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescence., PMID:23471463
PET imaging of CD105/endoglin expression with a ⁶¹/⁶⁴Cu-labeled Fab antibody fragment., PMID:23344138
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer., PMID:22767667
Endoglin-targeted cancer therapy., PMID:21034418
For research use only. Not for human or drug use.
